What is the recommended workup for a patient with suspected Tumor Lysis Syndrome (TLS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tumor Lysis Syndrome Workup

For any patient with suspected TLS, immediately obtain a comprehensive laboratory panel including uric acid, potassium, phosphorus, calcium, creatinine, BUN, and LDH, with monitoring frequency of every 6 hours for the first 24 hours in high-risk patients. 1

Essential Laboratory Studies

Core TLS Panel

  • Uric acid – critical for diagnosis; laboratory TLS defined by increase >25% from baseline or absolute value ≥8 mg/dL (476 mmol/L) 1
  • Potassium – assess for life-threatening hyperkalemia 2
  • Phosphorus – elevated due to massive cell lysis 2
  • Calcium – typically decreased secondary to hyperphosphatemia 2
  • Creatinine and BUN – evaluate renal function and acute kidney injury 1
  • Lactate dehydrogenase (LDH) – marker of cell turnover and tissue breakdown 2

Additional Required Studies

  • Complete blood count with differential – assess disease burden and cytopenias 2
  • Comprehensive metabolic panel – includes sodium and liver function tests 2
  • Disseminated intravascular coagulation (DIC) panel – D-dimer, fibrinogen, PT, PTT, particularly important in acute leukemia 2

Monitoring Frequency Based on Risk

High-Risk Patients

Monitor LDH, uric acid, sodium, potassium, creatinine, BUN, phosphorus, and calcium every 12 hours for the first three days, then every 24 hours subsequently. 1 High-risk features include bulky disease (≥10 cm), elevated LDH, high white blood cell count, pre-existing renal impairment, and elevated baseline uric acid. 3

Established TLS

For patients with confirmed TLS, monitor vital parameters and complete laboratory panel every 6 hours for the first 24 hours, then daily thereafter until stable. 1

Imaging Studies

Risk Stratification Imaging

  • Chest X-ray – mandatory to rule out mediastinal mass and pleural effusion 2
  • CT scan – useful for assessment of TLS risk category before initiating venetoclax in CLL, and for evaluating bulky disease 2
  • CT/MRI of head with contrast – only if neurologic symptoms present to detect CNS bleeding or chloromas 2
  • Whole-body PET/CT – if lymphoblastic lymphoma suspected 2

Important caveat: Serial CT scans are not recommended for asymptomatic patients. 2

Renal Function Assessment

Use estimated glomerular filtration rate (eGFR) calculated by MDRD formula or Cockroft-Gault equation as reliable surrogates for renal excretion function. 1 Direct measurement of creatinine clearance or eGFR is essential for proper risk stratification and management decisions. 1

Additional Workup Components

Cardiac Assessment

  • Echocardiogram or cardiac nuclear medicine scan – required in all patients who will receive anthracyclines, particularly those with prior cardiac history, prior anthracycline exposure, cardiac symptoms, or elderly patients 2

Infection Screening

  • Screen for opportunistic infections as clinically appropriate, especially if febrile or symptomatic 2
  • Initiate empiric anti-infective therapy when indicated 2

Special Populations

  • Pregnancy testing – for all patients of childbearing potential 2
  • Testicular examination with scrotal ultrasound – as indicated in male patients, particularly with T-cell ALL where testicular involvement is more common 2

Clinical TLS Definition

Clinical TLS requires laboratory TLS (abnormalities in ≥2 parameters: uric acid, potassium, phosphorus, calcium) PLUS at least one of the following within 7 days: 1, 4

  • Renal failure/injury (creatinine >1.5× upper limit of normal)
  • Need for renal dialysis
  • Cardiac arrhythmia
  • Seizure

Critical Pitfalls to Avoid

  • Do not delay laboratory monitoring – waiting for symptoms to develop before checking labs can result in life-threatening complications 1
  • Do not rely on single time-point measurements – TLS develops rapidly and requires serial monitoring 1
  • Do not overlook pre-existing renal impairment – this significantly increases TLS risk and requires more aggressive monitoring 3
  • Do not use calcium gluconate for mild hypocalcemia – can precipitate calcium-phosphate crystals in setting of hyperphosphatemia 1

References

Guideline

Laboratory Monitoring in Tumor Lysis Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Prevention of Tumor Lysis Syndrome in B-Cell Lymphoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.